Unjha Formulations Share Price Today | Stock Price & Unjha Formulations Share Screener
As of November 18, 2026, the live Unjha Formulations share price (BSE: UNJHAFOR) is ₹27.98, up 2.68% from the previous close, with shares trading between ₹26.00 and ₹28.06 in today's trading session, and a 52-week range of ₹17.55–₹35.45. Track UNJHAFOR market capitalization to gauge the company's total market size. Use the Unjha Formulations stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Unjha Formulations opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Unjha Formulations Share Price Chart
Track the current stock price of Unjha Formulations with an interactive chart. Analyse UNJHAFOR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Unjha Formulations stock quote in one place.
The quote of ₹27.98 sits between the 52-week low of ₹17.55 and the 52-week high of ₹35.45, and the latest session moved 2.68% from the previous close.
Unjha Formulations Company Profile - Fundamental Screener
Screen Unjha Formulations company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for UNJHAFOR shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE576D01015.
Company Details
Classification
Identifiers and Leadership
Unjha Formulations Balance Sheet Screener
Screen UNJHAFOR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹6, up from ₹5 in 2025.
Latest statistics put total assets at ₹6 and shareholder funds at ₹4.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 6 | 5 | 5 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 4 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | -1 | -1 | -2 | -2 | -2 | -3 | -3 | -3 | -3 | -4 |
Unjha Formulations Income Statement Screener - Profit & Revenue Analysis
Screen Unjha Formulations income statement and profit fundamentals. Analyze UNJHAFOR quarterly results. Unjha Formulations reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹15 and net profit was ₹0, equal to earnings per unit of ₹0.40, at an operating margin of 2%.
In that period expenses were ₹15, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹16 and net profit of ₹1.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 15 | 16 | 14 | 19 | 13 | 14 | 10 | 11 | 12 | 11 | 12 | 10 | 9 |
| Expenses | 15 | 15 | 13 | 18 | 13 | 14 | 10 | 10 | 11 | 11 | 12 | 10 | 9 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Operating Profit % | 2.00% | 6.00% | 4.00% | 3.00% | 3.00% | 2.00% | 1.00% | 2.00% | 3.00% | 3.00% | 3.00% | 4.00% | 2.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.40 | 1.57 | 0.91 | 0.62 | 0.63 | 0.56 | 0.23 | 0.69 | 0.67 | 0.59 | 0.66 | 0.57 | 0.39 |
Unjha Formulations Cash Flow Screener - Liquidity Fundamentals
Screen UNJHAFOR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹1, and net cash flow was an inflow of ₹1.
Over the same period, investing activities provided ₹0 and financing activities provided ₹0.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 1 | 0 | 1 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 1 | 0 | 1 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
Unjha Formulations Shareholding Pattern Screener
See Unjha Formulations shareholding pattern with promoter, FII, and DII holdings. Check Unjha Formulations promoter holding and ownership changes for UNJHAFOR on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 36.92%, foreign institutions 0.00%, domestic institutions 0.00% and the public 55.53%, spread across 4,235 shareholders.
The shareholder count was 4,235 in 2026-Mar, compared with 4,223 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% | 36.92% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 55.53% | 55.48% | 56.72% | 56.80% | 56.10% | 56.19% | 56.14% | 58.13% |
| Other Holding | 7.54% | 7.60% | 6.35% | 6.28% | 6.98% | 6.88% | 6.94% | 4.95% |
| Shareholder Count | 4,235 | 4,223 | 4,443 | 4,273 | 4,213 | 4,284 | 4,251 | 3,933 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Unjha Formulations. Unjha Formulations dividend yield can be compared with peers and other stocks in the market.
Unjha Formulations Stock Index Membership - Nifty & Sensex
See which indices include Unjha Formulations stock. Check UNJHAFOR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Unjha Formulations Market Events Screener - Corporate Actions
Get Unjha Formulations corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Unjha Formulations stock events that may affect UNJHAFOR share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.
It is followed by Annual General Meeting dated August 14, 2026 and Quarterly Result Announcement dated August 3, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-05 | 2026-11-05 | Quarterly Result Announcement | NA | -5.87% |
| 2026-08-14 | 2026-08-14 | Annual General Meeting | NA | 42.11% |
| 2026-08-03 | 2026-08-03 | Quarterly Result Announcement | NA | -3.67% |
| 2026-05-18 | 2026-05-18 | Quarterly Result Announcement | NA | -4.01% |
| 2026-02-04 | 2026-02-04 | Quarterly Result Announcement | NA | -1.25% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | -2.76% |
| 2025-08-13 | 2025-08-13 | Annual General Meeting | NA | 2.42% |
| 2025-08-06 | 2025-08-06 | Quarterly Result Announcement | NA | -3.52% |
| 2025-05-16 | 2025-05-16 | Quarterly Result Announcement | NA | -1.32% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -2.81% |
| 2024-11-08 | 2024-11-08 | Quarterly Result Announcement | NA | 12.80% |
| 2024-08-16 | 2024-08-16 | Annual General Meeting | NA | 12.61% |
Unjha Formulations Competitors Screener - Peer Stocks Comparison
Screen UNJHAFOR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,076 | 41.10 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 294,139 | 90.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 178,438 | 84.50 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 119,949 | 98.10 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 118,902 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,011 | 41.70 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,656 | 39.40 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,490 | 48.40 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,223 | 26.40 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 90,393 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
Unjha Formulations Company Announcements - News & Reports Screener
Screen UNJHAFOR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 9, 2026.
The next most recent announcements are dated November 5, 2026 and November 5, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-09 | Publish Audited Financial Results For The Quarter And Half Year Ended As On 30/09/2026 Ref: Regulation - Reg. 33 (3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations 2015 | - |
| 2026-11-05 | Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September2026 And Out Come Of Board Meeting Held On 5Th November 2026. | - |
| 2026-11-05 | Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For Quarter Ended And Half Year Ended On 30Th September2026 And Out Come Of Board Meeting Held On 5Th November 2026. | - |
| 2026-10-22 | Board Meeting Intimation for Board Meeting - Date: 05.11.2026 (Un-Audited Financial Results For The Half Year And Quarter Ended On 30.09.2026) | - |
| 2026-10-22 | Board Meeting Intimation for Board Meeting - Date: 05.11.2026 (Un-Audited Financial Results For The Half Year And Quarter Ended On 30.09.2026) | - |
| 2026-10-22 | Reguation 40(9) Compliance Report For Six Month Ended As On 30.09.2026 | - |
| 2026-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-08 | Submissions Of XML File For Financial Statement I.E. Balance Sheet P&L Accounts And Cash Flow Statement As On 31.03.2026 (AGM Held On 14/08/2026) As Per SEBI (Listing Obligation And Disclosure Requirements) Regulations2015 | - |
| 2026-09-08 | Submissions Of XML File For Financial Statement I.E. Balance Sheet P&L Accounts And Cash Flow Statement As On 31.03.2026 (AGM Held On 14/08/2026) As Per SEBI (Listing Obligation And Disclosure Requirements) Regulations2015 | - |
| 2026-08-14 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-14 | Regulation (30) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations2015 Details Of Voting Results At The 32Th Annual General Meeting Of The Company | - |
| 2026-08-14 | Filing Of Distribution Schedule | - |
| 2026-08-14 | Cash Flow Statement For The Year Ended 31.03.2026 | - |
| 2026-08-14 | Cash Flow Statement For The Year Ended 31.03.2026 | - |
| 2026-08-14 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-05 | Publish Audited Financial Results For The Quarter And Year Ended As On 30/06/2026 | - |
| 2026-08-03 | Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended On 30Th June 2026 And Out Come Of Board Meeting Held On 3Rd August 2026 | - |
| 2026-08-03 | Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended On 30Th June 2026 And Out Come Of Board Meeting Held On 3Rd August 2026 | - |
| 2026-07-28 | E- Voting Facility At The Forthcoming Annual General Meeting & Intimation Of Fixation Of Cut-Off Date | - |
| 2026-07-20 | Regulation 30 & 34(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹27.98, within a 52-week range of ₹17.55 to ₹35.45. The P/E ratio is 77.70 and the P/B ratio is 2.86, with earnings per unit of ₹1.57. Market capitalisation stands at ₹12.51 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.